

ASX Announcement

8 March 2021

Cogstate Limited
ABN 80 090 975 723

Suite 117
425 Smith Street
Fitzroy Victoria 3065
Australia

P +61 3 9664 1300
F +61 3 9664 1301
W cogstate.com

Business Update

Quarterly Sales Contracts Executed To Date – Clinical Trials Segment

Cogstate (ASX.CGS) is pleased to announce that Clinical Trials sales contracts executed in 3Q21 to date (01 Jan 2021 - 05 Mar 2021) total US\$10.7 million, taking the total value of sales contracts executed in FY21 year-to-date to US\$33.3 million.

For context, a history of Clinical Trials sales contracts executed, per quarter, since 1 July 2017 is provided below:

	Sep Quarter US\$m	Dec Quarter US\$m	1 st Half US\$m	Mar Quarter US\$m	Jun Quarter US\$m	2 nd Half US\$m	Financial Year US\$m
FY21 YTD	\$8.3	\$14.3	\$22.6	\$10.7 ⁽¹⁾			
FY20	\$7.7	\$19.2	\$26.9	\$10.7	\$8.4	\$19.1	\$46.0
FY19	\$5.4	\$4.6	\$10.0	\$3.8	\$4.1	\$7.9	\$17.9
FY18	\$7.5	\$14.1	\$21.6	\$8.3	\$6.2	\$14.5	\$36.1 ⁽²⁾

⁽¹⁾ Quarter to date: For the period 01 Jan 2021 – 05 Mar 2021 only.

⁽²⁾ Does not take into account \$6.4m of study cancellations that were recognised at 30 June 2018.

This announcement was authorised for release by a sub-committee of the Board of Directors of Cogstate Ltd.

About Cogstate

Cogstate Ltd (ASX:CGS) is the neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company's clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting. For 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world. In the Healthcare market, in August 2019 Cogstate entered into an exclusive licensing agreement with the pharmaceutical company Eisai, under which Eisai will market Cogstate technologies as digital cognitive assessment tools in Japanese markets. In October 2020, Cogstate extended its agreement with Eisai to the Rest of the World. The product, branded as NouKNOW, launched in Japan on 31 March 2020 (nouknow.jp). For more information, please visit www.cogstate.com.

For further information contact:

Brad O'Connor, Chief Executive Officer, boconnor@cogstate.com